ArticleJMA journal2026
Prescription of Ninjin'yoeito, A Japanese Kampo Medicine, in Relation to Levels of Long-Term Care Needs or Disabilities in Older Adults: A Cross-Sectional Study.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ninjin'yoeito, a Japanese Kampo medicine, is expected to be effective for frailty, but its utilization in Japanese clinical practice is unknown. Thus, this study aimed to characterize older adults who were prescribed ninjin'yoeito in terms of long-term care (LTC) needs, physical and cognitive disabilities, and diagnoses. Methods: We conducted a population-based cross-sectional study using medical and LTC claims data for adults aged ≥75 years in 2019 in Hachioji City, Tokyo, Japan. LTC needs levels were classified into four categories: independent (including no certification), support level 1 or 2, care level 1 or 2, and care levels 3 to 5. Disability levels were categorized into nine groups based on the combination of levels of physical disability and cognitive impairment, which were assessed using nationally standardized measures at LTC needs certification. Multivariable logistic regression analyses were performed to evaluate the associations between ninjin'yoeito prescriptions during a three-month period and LTC needs or disability levels, adjusting for age and sex. We described the differences in the frequencies of International Classification of Diseases, Tenth Revision (ICD-10)-based diagnoses between participants with and without ninjin'yoeito prescriptions. Results: The study included 59,133 participants (median age, 80 years; 58.6% female). Ninjin'yoeito prescription prevalence was 0.22% (n = 130). Participants at support level 1 or 2, those at care level 1 or 2, and those who were independent living and had mild cognitive impairment were more likely to be prescribed ninjin'yoeito (adjusted odds ratio, 2.68; 95% confidence interval, 1.70-4.21; 1.91, 1.18-3.10; and 3.24, 2.04-5.15, respectively). Participants prescribed ninjin'yoeito were more likely to have diagnoses, including symptoms and signs related to food and fluid intake, malaise and fatigue, and dorsalgia. Conclusions: We identified the characteristics of community-dwelling older adults prescribed ninjin'yoeito. Our results may suggest that ninjin'yoeito was generally prescribed to older adults with frailty, within the indications of this formulation on the Japanese label.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.